vs
MEDALLION FINANCIAL CORP（MFIN）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
MEDALLION FINANCIAL CORP的季度营收约是RECURSION PHARMACEUTICALS, INC.的2.0倍（$70.6M vs $35.5M），MEDALLION FINANCIAL CORP净利率更高（17.3% vs -304.2%，领先321.5%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 25.4%），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 15.0%）
Mahindra & Mahindra金融服务有限公司（MMFSL）是一家印度农村非银行金融公司，总部位于孟买。该公司是印度头部拖拉机融资机构之一，在印度全国拥有超过一千家分支机构
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
MFIN vs RXRX — 直观对比
营收规模更大
MFIN
是对方的2.0倍
$35.5M
营收增速更快
RXRX
高出656.3%
25.4%
净利率更高
MFIN
高出321.5%
-304.2%
两年增速更快
RXRX
近两年复合增速
15.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $70.6M | $35.5M |
| 净利润 | $12.2M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 29.3% | -304.8% |
| 净利率 | 17.3% | -304.2% |
| 营收同比 | 25.4% | 681.7% |
| 净利润同比 | 20.3% | 39.6% |
| 每股收益（稀释后） | $0.50 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MFINRXRX
| Q4 25 | $70.6M | $35.5M | ||
| Q3 25 | $58.7M | $5.2M | ||
| Q2 25 | $62.6M | $19.2M | ||
| Q1 25 | $63.0M | $14.7M | ||
| Q4 24 | $56.3M | $4.5M | ||
| Q3 24 | $53.3M | $26.1M | ||
| Q2 24 | $51.0M | $14.4M | ||
| Q1 24 | $53.3M | $13.8M |
净利润MFINRXRX
| Q4 25 | $12.2M | $-108.1M | ||
| Q3 25 | $7.8M | $-162.3M | ||
| Q2 25 | $11.1M | $-171.9M | ||
| Q1 25 | $12.0M | $-202.5M | ||
| Q4 24 | $10.1M | $-178.9M | ||
| Q3 24 | $8.6M | $-95.8M | ||
| Q2 24 | $7.1M | $-97.5M | ||
| Q1 24 | $10.0M | $-91.4M |
毛利率MFINRXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率MFINRXRX
| Q4 25 | 29.3% | -304.8% | ||
| Q3 25 | 33.2% | -3327.6% | ||
| Q2 25 | 31.1% | -916.8% | ||
| Q1 25 | 32.1% | -1297.9% | ||
| Q4 24 | 32.8% | -4042.4% | ||
| Q3 24 | 26.6% | -377.1% | ||
| Q2 24 | 24.3% | -697.4% | ||
| Q1 24 | 33.6% | -698.4% |
净利率MFINRXRX
| Q4 25 | 17.3% | -304.2% | ||
| Q3 25 | 13.2% | -3135.3% | ||
| Q2 25 | 17.7% | -894.2% | ||
| Q1 25 | 19.1% | -1373.3% | ||
| Q4 24 | 18.0% | -3935.5% | ||
| Q3 24 | 16.1% | -367.5% | ||
| Q2 24 | 13.9% | -676.6% | ||
| Q1 24 | 18.8% | -662.4% |
每股收益（稀释后）MFINRXRX
| Q4 25 | $0.50 | $-0.17 | ||
| Q3 25 | $0.32 | $-0.36 | ||
| Q2 25 | $0.46 | $-0.41 | ||
| Q1 25 | $0.50 | $-0.50 | ||
| Q4 24 | $0.43 | $-0.56 | ||
| Q3 24 | $0.37 | $-0.34 | ||
| Q2 24 | $0.30 | $-0.40 | ||
| Q1 24 | $0.42 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $136.3M | $743.3M |
| 总债务越低越好 | $216.0M | $9.6M |
| 股东权益账面价值 | $408.6M | $1.1B |
| 总资产 | $3.0B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.53× | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资MFINRXRX
| Q4 25 | $136.3M | $743.3M | ||
| Q3 25 | $72.5M | $659.8M | ||
| Q2 25 | $110.4M | $525.1M | ||
| Q1 25 | $131.5M | $500.5M | ||
| Q4 24 | $98.2M | $594.4M | ||
| Q3 24 | $120.6M | $427.6M | ||
| Q2 24 | $87.7M | $474.3M | ||
| Q1 24 | $54.8M | $296.3M |
总债务MFINRXRX
| Q4 25 | $216.0M | $9.6M | ||
| Q3 25 | $215.7M | $11.9M | ||
| Q2 25 | $199.9M | $14.2M | ||
| Q1 25 | $199.7M | $16.4M | ||
| Q4 24 | $232.2M | $19.0M | ||
| Q3 24 | $232.0M | $20.5M | ||
| Q2 24 | $230.8M | $22.9M | ||
| Q1 24 | $225.6M | — |
股东权益MFINRXRX
| Q4 25 | $408.6M | $1.1B | ||
| Q3 25 | $397.4M | $1.0B | ||
| Q2 25 | $389.9M | $919.1M | ||
| Q1 25 | $380.2M | $933.9M | ||
| Q4 24 | $370.2M | $1.0B | ||
| Q3 24 | $362.4M | $524.6M | ||
| Q2 24 | $354.0M | $584.4M | ||
| Q1 24 | $349.0M | $401.2M |
总资产MFINRXRX
| Q4 25 | $3.0B | $1.5B | ||
| Q3 25 | $2.9B | $1.4B | ||
| Q2 25 | $2.9B | $1.3B | ||
| Q1 25 | $2.8B | $1.3B | ||
| Q4 24 | $2.9B | $1.4B | ||
| Q3 24 | $2.9B | $726.5M | ||
| Q2 24 | $2.8B | $775.9M | ||
| Q1 24 | $2.6B | $557.8M |
负债/权益比MFINRXRX
| Q4 25 | 0.53× | 0.01× | ||
| Q3 25 | 0.54× | 0.01× | ||
| Q2 25 | 0.51× | 0.02× | ||
| Q1 25 | 0.53× | 0.02× | ||
| Q4 24 | 0.63× | 0.02× | ||
| Q3 24 | 0.64× | 0.04× | ||
| Q2 24 | 0.65× | 0.04× | ||
| Q1 24 | 0.65× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $126.3M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.3M |
| 自由现金流率自由现金流/营收 | — | -133.1% |
| 资本支出强度资本支出/营收 | — | 3.5% |
| 现金转化率经营现金流/净利润 | 10.35× | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
经营现金流MFINRXRX
| Q4 25 | $126.3M | $-46.1M | ||
| Q3 25 | $67.0M | $-117.4M | ||
| Q2 25 | $-10.7M | $-76.4M | ||
| Q1 25 | $36.3M | $-132.0M | ||
| Q4 24 | $108.7M | $-115.4M | ||
| Q3 24 | $24.6M | $-59.2M | ||
| Q2 24 | $27.6M | $-82.2M | ||
| Q1 24 | $32.3M | $-102.3M |
自由现金流MFINRXRX
| Q4 25 | — | $-47.3M | ||
| Q3 25 | — | $-117.6M | ||
| Q2 25 | — | $-79.6M | ||
| Q1 25 | — | $-133.8M | ||
| Q4 24 | — | $-116.7M | ||
| Q3 24 | — | $-63.8M | ||
| Q2 24 | — | $-83.4M | ||
| Q1 24 | — | $-109.0M |
自由现金流率MFINRXRX
| Q4 25 | — | -133.1% | ||
| Q3 25 | — | -2272.5% | ||
| Q2 25 | — | -413.9% | ||
| Q1 25 | — | -907.4% | ||
| Q4 24 | — | -2567.7% | ||
| Q3 24 | — | -244.6% | ||
| Q2 24 | — | -578.5% | ||
| Q1 24 | — | -789.9% |
资本支出强度MFINRXRX
| Q4 25 | — | 3.5% | ||
| Q3 25 | — | 4.7% | ||
| Q2 25 | — | 16.4% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | — | 28.6% | ||
| Q3 24 | — | 17.5% | ||
| Q2 24 | — | 8.2% | ||
| Q1 24 | — | 48.2% |
现金转化率MFINRXRX
| Q4 25 | 10.35× | — | ||
| Q3 25 | 8.63× | — | ||
| Q2 25 | -0.97× | — | ||
| Q1 25 | 3.02× | — | ||
| Q4 24 | 10.72× | — | ||
| Q3 24 | 2.86× | — | ||
| Q2 24 | 3.89× | — | ||
| Q1 24 | 3.22× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
